Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 25 articles: HTML format

Single Articles

September 2025
1. SU K, Hou XR, Zhong QZ, Liu X, et al
   Survival benefit of adjuvant radiotherapy following asparaginase-based chemotherapy in patients with chemo-responsive advanced-stage extranodal NK/T-cell lymphoma: A multicenter study using the CLCG database.
   Int J Radiat Oncol Biol Phys. 2025 Sep 17:S0360-3016(25)06278.
   PubMed     Abstract available
   
   
   July 2025
2. KUMAR KA, Zhong X, Iqbal Z, Geethakumari PR, et al
   Adaptive Radiation Therapy in Lymphomas: Indications, Early Experiences, and Future Directions.
   Int J Radiat Oncol Biol Phys. 2025;122:926-935.
   PubMed     Abstract available
   
   
   
3. CAMPBELL BA, Gabriel G, Delaney GP, Porceddu SV, et al
   Radiation therapy utilization for primary cutaneous T-cell lymphoma is lowest amongst patients living in the most geographically accessible areas; an Australian study: Disparate RT-utilization in patients with CTCL.
   Int J Radiat Oncol Biol Phys. 2025 Jul 13:S0360-3016(25)04645.
   PubMed     Abstract available
   
   
   June 2025
4. HOPPE BS, Mailhot-Vega RB, Renfro LA, Pei Q, et al
   Comparison of Contemporary Radiotherapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331.
   Int J Radiat Oncol Biol Phys. 2025 Jun 28:S0360-3016(25)04518.
   PubMed     Abstract available
   
   
   
5. MILGROM SA, Lo AC, Parikh RR
   Transplant-Free Salvage of Relapsed/Refractory Classic Hodgkin Lymphoma in Children, Adolescents, and Young Adults: An Emerging Role for Radiation Therapy.
   Int J Radiat Oncol Biol Phys. 2025;122:213-219.
   PubMed    
   
   
   May 2025
6. PEREZ P, Figura NB
   Classic Radiation, Modern Precision: A Timeless Cure for Hodgkin Lymphoma.
   Int J Radiat Oncol Biol Phys. 2025;122:8.
   PubMed    
   
   
   
7. DIBS K, Sim AJ
   A Blast From the Past: Definitive Management of Favorable Early-Stage Hodgkin Lymphoma Ineligible for Systemic Therapy.
   Int J Radiat Oncol Biol Phys. 2025;122:5-6.
   PubMed    
   
   
   April 2025
8. ABABNEH HS, Ng AK, Wan J, Walburn T, et al
   5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma.
   Int J Radiat Oncol Biol Phys. 2025 Apr 3:S0360-3016(25)00251.
   PubMed     Abstract available
   
   
   March 2025
9. ELSAYAD K, Guenova E, Fournier B, Fernandes C, et al
   Real-World Pattern-of-Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members.
   Int J Radiat Oncol Biol Phys. 2025;121:1006-1010.
   PubMed     Abstract available
   
   
   
10. TRAN K, Oh D, Tsang R, Suh CO, et al
    An International Lymphoma Radiation Oncology Group study of radiotherapy for bilateral indolent orbital adnexal lymphomas.
    Int J Radiat Oncol Biol Phys. 2025 Mar 14:S0360-3016(25)00241.
    PubMed     Abstract available
    
    
    February 2025
11. HUANG CC, Wan Z, Niedzwiecki D, Prosnitz LR, et al
    Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma.
    Int J Radiat Oncol Biol Phys. 2025 Feb 22:S0360-3016(25)00150.
    PubMed     Abstract available
    
    
    January 2025
12. ROBERTI S, Russell NS, Pfeiffer RM, Krul IM, et al
    Radiation doses to the breast and predicted breast cancer risk among patients treated for Hodgkin lymphoma with modern radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025 Jan 8:S0360-3016(24)03775.
    PubMed     Abstract available
    
    
    November 2024
13. TRINGALE KR, Grommes C, Ucpinar BA, Reiner AS, et al
    Consolidation Regimen and Cerebral Atrophy in Patients with Primary Central Nervous System Lymphoma.
    Int J Radiat Oncol Biol Phys. 2024 Nov 28:S0360-3016(24)03661.
    PubMed     Abstract available
    
    
    
14. TSENG YD, Stevenson P, Nguyen B, Li DC, et al
    Impact of Myc-Altered Pathology on Radiotherapy Efficacy Among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Study by XXX: Impact of double hit pathology on RT efficacy.
    Int J Radiat Oncol Biol Phys. 2024 Nov 14:S0360-3016(24)03642.
    PubMed     Abstract available
    
    
    October 2024
15. JEON SH, Chang JH, Kim IH, Yoon HI, et al
    Reduced-dose radiotherapy for stage IE gastric mucosa-associated lymphoid tissue lymphoma: a multi-institutional prospective study (KROG 16-18).
    Int J Radiat Oncol Biol Phys. 2024 Oct 22:S0360-3016(24)03513.
    PubMed     Abstract available
    
    
    September 2024
16. MANZAR GS, Wu SY, Dudzinski SO, Cha EE, et al
    Characterization of lymphopenia and correlating the risk of cytopenias with dose and BM volume irradiated in aggressive B-cell lymphoma patients bridged with radiation therapy for CAR-T cell therapy.
    Int J Radiat Oncol Biol Phys. 2024 Sep 18:S0360-3016(24)03394.
    PubMed     Abstract available
    
    
    
17. LO AC, Parikh RR, Kamdar M, Milgrom SA, et al
    At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;120:1-9.
    PubMed    
    
    
    July 2024
18. MCCAMMACK E, Terezakis S
    Extirpation in Nodal DLBCL: What and Where Is the Relapse Risk?
    Int J Radiat Oncol Biol Phys. 2024;119:718.
    PubMed    
    
    
    
19. MCMULLEN KP, Sawyer J
    Resected Diffuse Large B Cell Lymphoma: Does Extirpation Mean No Irradiation in the PET-Response Based Milieu?
    Int J Radiat Oncol Biol Phys. 2024;119:716-717.
    PubMed    
    
    
    June 2024
20. COOPER BT, Mayo CS, Milano MT, Olch AJ, et al
    Predictive Factors Associated With Radiation Myelopathy in Pediatric Patients With Cancer: A PENTEC Comprehensive Review.
    Int J Radiat Oncol Biol Phys. 2024;119:494-506.
    PubMed     Abstract available
    
    
    
21. LO AC, Ronckers C, Aznar MC, Avanzo M, et al
    Breast Hypoplasia and Decreased Lactation From Radiation Therapy in Survivors of Pediatric Malignancy: A PENTEC Comprehensive Review.
    Int J Radiat Oncol Biol Phys. 2024;119:549-559.
    PubMed     Abstract available
    
    
    April 2024
22. ROSENBROCK J, Kaul H, Oertel M, Celik E, et al
    Involved-site radiotherapy is equally effective and less toxic than Involved-field radiotherapy in patients receiving combined modality treatment for early-stage unfavorable Hodgkin lymphoma - an analysis of the randomized phase III HD17 trial of the
    Int J Radiat Oncol Biol Phys. 2024 Apr 15:S0360-3016(24)00514.
    PubMed     Abstract available
    
    
    
23. PARIKH RR, Milgrom SA, Campbell BA
    Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Int J Radiat Oncol Biol Phys. 2024;118:1152-1158.
    PubMed    
    
    
    November 2023
24. NIU S, Li Y, Shao H, Hu J, et al
    Phase II clinical trial of simultaneous-boost IMRT with three dose gradients in patients with stage I-II nasal type natural killer/T-cell lymphoma: long-term outcomes of survival and quality of life: Simultaneous-boost intensity-modulated radiotherapy
    Int J Radiat Oncol Biol Phys. 2023 Nov 6:S0360-3016(23)07944.
    PubMed    
    
    
    September 2023
25. ELSAYAD K, Weishaupt C, Moustakis C, Danzer MF, et al
    Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sezary Syndrome.
    Int J Radiat Oncol Biol Phys. 2023;117:164-170.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.